RYLPF (Koninklijke Philips NV) Research & Development: $1,905 Mil (TTM As of Mar. 2026)


RYLPF Koninklijke Philips NV RYLPF
73 GF Score
Price $26.19
GF Value $25.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Koninklijke Philips NV Research & Development?

Koninklijke Philips NV RYLPF 73 Research & Development is $1,905 Mil as of Mar. 2026. GuruFocus rates RYLPF with a GF Score™ of 73/100 and a GF Value™ of $25.13 (Fairly Valued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Koninklijke Philips NV's Research & Development for the three months ended in Mar. 2026 was $455 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $1,905 Mil.

Koninklijke Philips NV  (OTCPK:RYLPF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Koninklijke Philips NV Research & Development Related Terms

Koninklijke Philips NV Research & Development Historical Data

* Premium members only.

The historical data trend for Koninklijke Philips NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Koninklijke Philips NV Research & Development Chart

Koninklijke Philips NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,040.68 2,215.04 2,061.07 1,829.32 1,990.63

Koninklijke Philips NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 494.05 463.67 485.92 500.00 455.49
RYLPF
73GF Score
Koninklijke Philips NV RYLPF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Koninklijke Philips NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,905 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1,905 Mil mean?
Koninklijke Philips NV (RYLPF) has a Research & Development of $1,905 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Koninklijke Philips NV and its competitors.
Is Koninklijke Philips NV's Research & Development too high?
Koninklijke Philips NV's current Research & Development is $1,905 Mil. Overall, Koninklijke Philips NV has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Koninklijke Philips NV's Research & Development compare to ABT and SYK?
Koninklijke Philips NV's Research & Development of $1,905 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Koninklijke Philips NV and its competitors. Koninklijke Philips NV's current Research & Development is $1,905 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Koninklijke Philips NV stock overvalued right now?
Based on GuruFocus' analysis, Koninklijke Philips NV (RYLPF) is currently considered Fairly Valued. The stock's GF Value™ is $25.13, compared to a current price of $26.19 — trading 4.2% above its estimated fair value. The current Research & Development is $1,905 Mil. Koninklijke Philips NV's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Koninklijke Philips NV (RYLPF), the current Research & Development is $1,905 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Koninklijke Philips NV (RYLPF) Overvalued in 2026?

Based on GuruFocus' analysis, Koninklijke Philips NV stock appears to be overvalued. The current stock price of $26.19 is trading 4.2% above its estimated GF Value™ of $25.13. GuruFocus considers Koninklijke Philips NV to be Fairly Valued.

Key valuation signals for RYLPF:

  • Research & Development: $1,905 Mil
  • GF Value™: $25.13 vs. price of $26.19 (4.2% above fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the RYLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Koninklijke Philips NV Business Description

Address Prinses Irenestraat 59, Amsterdam, NLD, 1077 WV
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound and X-ray equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
73GF Score

Get the complete analysis for RYLPF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.19
Price
$25.13
GF Value